Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Refocus On China: Ark Bio Evolves As It Plans Shanghai Listing

Eyes R&D In Less Crowded Sectors

Executive Summary

Shanghai-based Ark Biosciences has expanded its pipeline from the RSV-targeting drug ziresovir, licensed from Roche, to pediatric and fibrosis treatments, where there are largely untapped opportunities in China. In a strategy shift, the company is betting on the domestic market instead of going global.

You may also be interested in...



Ark Bio Of China Bets On Untapped Pediatric Antiviral Market Where Few Have Succeeded

Founded five years ago, Shanghai-based Ark Bio sees big potential in the less crowded pediatric antiviral treatment market. Now the start-up is in Phase II development for its lead asset ziresovir for respiratory syncytial virus (RSV) infection, which was licensed from Roche.

Orphan Drug, Domestic Developers Shine In China Annual Approvals Tally

10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.

Hidden Dragon? Investors Return To New China Biotech Reality

Several Chinese biotech developments during the Lunar New Year break have put investors on high alert, namely the continued share price slide of Chinese biotech bellwether WuXi Apptec, Lianbio ceasing operations and I-Mab divesting its China business to become a fully US-focused company.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel